[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"RenJi Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":624},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,166,0,25,[9,48,76,106,126,145,166,192,214,240,269,301,321,355,375,401,424,446,469,487,508,536,555,576,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652243","retlirafusp-alfa-combined-with-chemoradiotherapy-in-unresectable-escc-100652243",false,"NCT07769866","Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC","Retlirafusp Alfa Combined With Definitive Concurrent Chemoradiotherapy in Local Advanced Unresectable Esophageal Squamous Cell Cancer","Inclusion Criteria:\n\n1. Voluntarily sign the written informed consent form and agree to participate in this study;\n2. Pathologically confirmed esophageal squamous cell carcinoma;\n3. Staged as T2-4bN0-3M0 or TXNXM1 (with supraclavicular lymph node metastasis), diagnosed as unresectable locally advanced esophageal cancer (according to the American Joint Committee on Cancer (AJCC) 8th edition);\n4. Aged 18-75 years, male or female;\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n6. No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc.;\n7. Adequate major organ function, meeting the following laboratory criteria:\n\n   Complete blood count: Neutrophil count ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Blood biochemistry: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL\u002Fmin; Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;\n8. Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug, and must use effective contraception during the study period and for at least 3 months after the last dose; Male patients with female partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study period and for 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Prior or concurrent treatment with any of the following:\n\n   1. Any prior or ongoing radiotherapy, chemotherapy, or other anti-tumor agents for malignancy;\n   2. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (at a dose \\> 10 mg\u002Fday of prednisone or equivalent) within 2 weeks prior to the first dose of study drug. Inhaled or topical corticosteroids, and adrenal hormone replacement at doses \\> 10 mg\u002Fday prednisone or equivalent, are permitted in the absence of active autoimmune disease;\n   3. Receipt of live attenuated vaccines within 4 weeks prior to the first dose of study drug;\n   4. Major surgery or severe trauma within 4 weeks prior to the first dose of study drug;\n2. Tumor-related exclusion criteria:\n\n   1. Non-esophageal cancer patients;\n   2. Patients without unresectable locally advanced or metastatic esophageal cancer;\n   3. Diagnosis of another malignancy within 5 years prior to the first dose of study drug, with the exception of cured cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery;\n3. Other criteria:\n\n   1. Poorly controlled cardiac symptoms or diseases, including: a) New York Heart Association (NYHA) class ≥ 2 heart failure; b) Unstable angina; c) Myocardial infarction within 1 year; d) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n   2. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; asthma requiring bronchodilators for medical intervention is excluded;\n   3. Pregnant or breastfeeding women;\n   4. History of severe allergic reactions to monoclonal antibodies, platinum agents, paclitaxel, or human serum albumin;\n   5. Human immunodeficiency virus (HIV)-positive patients, or patients with active hepatitis (hepatitis B reference: hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA (HBV DNA) ≥ 2000 IU\u002FmL or ≥ 10⁴ copies\u002FmL; hepatitis C reference: hepatitis C virus (HCV) antibody positive), or active pulmonary tuberculosis;\n   6. Any other condition that, in the investigator's judgment, may necessitate premature termination from the study.","ALL","18 Years","75 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma. Participants will receive two cycles of retlirafusp alfa and chemotherapy for induction therapy before standard concurrent chemoradiotherapy and retlirafusp alfa for maintenance treatment till one year.",[28],"Esophageal Squamous Cell Cancer",[28,30,31,32,33,34],"PD-L1","TGF-β","Retlirafusp Alfa","SHR-1701","concurrent chemoradiotherapy","NOT_YET_RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-18","ACTUAL",{"date":41,"type":22},"2026-09-01",{"date":43,"type":22},"2030-06-30",{"name":45,"class":46},"RenJi Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100651586","ficb-for-hip-fracture-pain-in-elderly-100651586","NCT07762846","FICB for Hip Fracture Pain in Elderly","The Early Intervention of Fascia Iliaca Compartment Block (FICB) as Pain Management for Elderly Patients With Hip Fracture to Improve Postoperative Rehabilitation: A Prospective Randomized Controlled Study","FICB-PREP","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Diagnosis of unilateral hip fracture (including femoral neck fracture or intertrochanteric fracture) confirmed by any imaging modality (X-ray, CT, or MRI)\n* Scheduled for hip fracture surgery under general anesthesia with endotracheal intubation (including total hip arthroplasty, hemiarthroplasty, intertrochanteric intramedullary nail fixation, closed reduction and internal fixation, etc.)\n* American Society of Anesthesiologists (ASA) physical status classification I-III\n* Able to provide written informed consent personally or via a legally authorized representative\n* Able to communicate normally in Chinese\n\nExclusion Criteria:\n\n* Known allergy to ropivacaine, bupivacaine, or liposomal bupivacaine\n* Presence of any contraindication to nerve block, including but not limited to: nerve injury, coagulopathy, severe infection at the injection site, exudate at the injection site, etc.\n* Pre-existing psychiatric or neurological disorders, including but not limited to: depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis\n* Pre-existing severe cardiac, pulmonary, hepatic, or renal dysfunction, including but not limited to: history of heart failure, requiring dialysis, etc.\n* Inability to communicate preoperatively (e.g., coma, dementia)\n* Preoperative pain score \\\u003C 4 on Visual Analog Scale (VAS) or chronic\u002Fold hip fracture\n* Currently participating in another interventional clinical trial\n* Any other condition that, in the opinion of the investigator, would preclude evaluation of the therapeutic response or make it unlikely that the patient will complete the expected treatment course and follow-up","65 Years",{"count":58,"type":22},144,[25],"Hip fracture is a common injury in elderly patients, often requiring surgical treatment. However, these patients frequently experience severe postoperative pain, which can delay mobility and recovery, and increase the risk of complications such as delirium, pneumonia, and prolonged hospital stay.\n\nThe fascia iliaca compartment block (FICB) is a regional anesthesia technique that has been shown to provide effective pain relief for hip fracture patients. This study aims to investigate whether early administration of FICB, performed upon hospital admission before surgery, can improve postoperative rehabilitation outcomes in elderly patients with hip fracture.\n\nThis is a prospective, randomized, controlled study. A total of 144 elderly patients with hip fracture will be randomly assigned to either the FICB group or the control group. The FICB group will receive ultrasound-guided FICB after being admitted to the orthopaedic ward, while the control group will receive standard analgesic care once inside the operating room.\n\nThe primary outcome measure is Quality of Recovery-15 score (QoR-15 score) 24 hours post-surgery. Secondary outcomes include: QoR-15 score at 48 hours postoperatively, NRS scores and sleep duration and quality scores at preoperative and various postoperative time points, total perioperative consumption of opioids and other analgesic drugs, extubation time and emergence agitation during anesthesia recovery period, incidence of delirium from postoperative period to before discharge, length of hospital stay, and overall satisfaction score with pain management.\n\nThe hypothesis of this study is that early FICB intervention, compared to standard care, will lead to better pain control, earlier mobilization, shorter hospital stay, and improved overall postoperative recovery in elderly patients with hip fracture.",[62,63,64,65,66,67],"Hip Fractures (i.e. Femoral Neck or Intertrochanteric Hip Fractures)","Postoperative Pain","QoR-15","Fascia Iliaca Block","Recovery of Function (G11.427.698.620)","Elderly","2026-08-12",{"date":70,"type":39},"2026-08-13",{"date":72,"type":22},"2026-08",{"date":74,"type":22},"2027-12",{"name":45,"class":46},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100651089","mirna-panel-for-pca-diagnosis-100651089","NCT07755592","miRNA Panel for PCa Diagnosis","Efficacy Exploration of Non-Invasive Diagnostic Strategies for Prostate Cancer (PCa) and Benign Prostatic Hyperplasia (BPH) Based on Body Fluid miRNA Panels: A Prospective Diagnostic Study","Inclusion Criteria:\n\nMale participants aged ≥18 years Serum PSA \\> 4.0 ng\u002FmL confirmed by repeat testing with ≥4-week interval, excluding interfering conditions such as acute urinary retention, catheterization and prostatitis PSA within gray zone (4.0-10.0 ng\u002FmL) accompanied by abnormal f\u002Ft PSA ratio \\\u003C0.16, PSAD \\>0.15 ng\u002FmL\u002Fg or PSAV \\>0.75 ng\u002FmL\u002Fyear Persistently rising PSA on two consecutive tests with abnormal PSAV regardless of absolute PSA value Abnormal digital rectal examination (DRE): palpable hard, nodular, fixed or asymmetric prostate lesions, indistinct induration or suspected space-occupying lesions Suspicious transrectal ultrasound (TRUS): hypoechoic nodules, hypervascular areas or disrupted prostatic capsule mpMRI PI-RADS v2.1 score ≥3, especially lesions scoring 4-5 Elevated focal PSMA uptake on PSMA PET\u002FCT (if performed) First-degree relative with prostate cancer and personal PSA \\>3.0 ng\u002FmL Carriers of pathogenic BRCA1\u002F2, HOXB13 mutations with PSA \\>3.0 ng\u002FmL Prior negative prostate biopsy with subsequent sustained PSA elevation or new suspicious mpMRI lesions Unexplained bone pain or pathological fracture with elevated PSA requiring exclusion of primary prostate malignancy Aggravated bladder outlet obstruction with elevated PSA or abnormal DRE requiring differentiation of malignant obstruction\n\nExclusion Criteria:\n\nConfirmed prostate cancer receiving radical surgery, radiotherapy, androgen deprivation therapy or active surveillance Acute bacterial prostatitis, febrile urinary tract infection or acute urinary retention within the preceding 4 weeks Prostate massage, cystoscopy, ejaculation within 72 hours; prostate biopsy within 6 weeks; transurethral prostate surgery within 3 months prior to screening Active concurrent malignancy or history of any malignant tumor within the past 5 years (non-melanoma skin cancer excluded) Severe Child-Pugh grade C liver dysfunction, eGFR \\\u003C30 mL\u002Fmin\u002F1.73m², coagulopathy (INR \\>1.5 or platelet count \\\u003C50×10⁹\u002FL) Unable to discontinue anticoagulants (warfarin, dabigatran, rivaroxaban) or dual antiplatelet therapy for ≥5 days Severe cognitive impairment or acute psychiatric disorder precluding independent informed consent, follow-up and biospecimen collection Participation in other interventional clinical trials within 3 months or concurrent observational trials interfering with study outcomes Hematological disorders including myelodysplastic syndrome and leukemia that alter serum nucleic acid stability Severe peripheral vascular disease hindering venipuncture or inability to comply with fasting blood collection requirements","MALE",{"count":85,"type":22},500,"30 Days","OBSERVATIONAL","This is a single-center, prospective diagnostic accuracy trial conducted at Renji Hospital, Shanghai Jiao Tong University School of Medicine, led by a team of urology and molecular medicine researchers. A total of 500 male participants aged 18 years or older who meet clinical indications for prostate biopsy will be enrolled between May 2026 and May 2027. All participants have suspected prostate cancer (PCa) based on abnormal prostate-specific antigen (PSA), abnormal digital rectal examination (DRE), suspicious multiparametric MRI (mpMRI), positive family history of prostate cancer, pathogenic gene mutations, or other high-risk clinical findings. Men with confirmed treated prostate cancer, recent prostate-related procedures, active other malignancies, severe organ dysfunction, coagulation disorders, or cognitive impairment that prevents informed consent will be excluded.\n\nThe core goal of this study is to test the diagnostic performance of a novel non-invasive blood test using a panel of circulating microRNAs (miRNAs) from serum, and compare it with the standard PSA-based screening tools to distinguish prostate cancer from benign prostatic hyperplasia (BPH). The gold standard for judging true disease status will be pathology results from transrectal ultrasound-guided prostate biopsy. Researchers will calculate key diagnostic metrics including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the ROC curve (AUC) for the miRNA panel. Secondary analyses will evaluate whether combining the miRNA signature with PSA or mpMRI improves diagnostic accuracy, especially for men with PSA levels in the ambiguous \"gray zone\" of 4-10 ng\u002FmL. Subgroup assessments will also test how well the miRNA panel differentiates low-risk versus high-risk prostate cancer and clinically significant versus insignificant tumors across different PSA tiers, age groups, mpMRI risk scores and prostate sizes. Additional laboratory testing will confirm the stability of serum miRNAs under different storage temperatures and storage durations, as well as test consistency across operators, reagent batches and detection platforms to validate real-world clinical usability.\n\nFor participants, the study only involves a one-time fasting venous blood draw of up to 10 mL before biopsy, with no extra invasive procedures or experimental medications added to routine clinical care. The free miRNA test results can serve as supplementary evidence to help doctors judge whether a prostate biopsy is truly necessary, potentially sparing many patients from unnecessary invasive biopsy and its associated discomfort or complications. All blood samples will be stored under standardized biosafety protocols with de-identified personal data to fully protect participant privacy. Minimal risks include minor temporary bruising or slight pain at the blood draw site, which resolve spontaneously without long-term harm.\n\nStatistical analysis will use three defined datasets (full analysis set, per-protocol set, safety set) and advanced methods including DeLong's test, logistic regression, NRI and IDI to quantify diagnostic improvement versus PSA. A 70% training cohort will build the miRNA diagnostic model, and the remaining 30% of samples will act as an independent validation group to verify model reliability. Safety monitoring will record all adverse events throughout follow-up, with strict ethical oversight following the Declaration of Helsinki and Chinese biomedical research regulations. After sample testing, data analysis and result summarization finish by October 2027, the research team plans to publish 1-2 peer-reviewed SCI papers to share findings globally. If validated, this serum miRNA panel will provide a more precise, non-invasive screening tool to reduce overdiagnosis and unnecessary prostate biopsies, optimize early prostate cancer detection, and lower overall medical burdens for men at risk of prostate disease in clinical practice.",[90],"Prostate Cancer (Diagnosis)",[92,93,94,95,96],"Prostate cancer","BPH","miRNA","serum biomarker","diagnosis","RECRUITING","2026-08-08",{"date":100,"type":39},"2026-08-11",{"date":102,"type":39},"2026-04-13",{"date":104,"type":22},"2027-12-01",{"name":45,"class":46},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":19,"enrollmentInfo":113,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":47},"100552178","a-trial-to-evaluate-the-effect-of-applying-leukapheresis-to-enrich-ctcs-in-mpca-patients-100552178","NCT06469710","A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients","A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in Patients With Metastatic Prostate Cancer","Inclusion Criteria:\n\n1. male, aged 18-75 years; and\n2. Evidence of metastasis (positive finding of metastasis on one of the following tests: CT and MRI; whole-body nuclear bone imaging, fluoride PET and PET-CT, cholinergic PET-CT and MRI; prostate-specific membrane antigen-targeted PET-CT); or clinical diagnosis of metastatic prostate cancer (tumour stage of T3 and above) by pathology of aspiration\u002Fsurgical biopsy;\n3. Good general condition, ECOG score 0-1, able to tolerate leukapheresis;\n4. Normal haematological analysis, liver and renal function tests at screening;\n5. Subjects (or their legal representatives) can understand the informed consent form.\n\nExclusion Criteria:\n\n1. those who have received systemic combination therapy for tumours within 5 years;\n2. those with poor general condition, severe haemodynamic instability, malignant arrhythmias, cachexia and infections\n3. those with coagulation disorders, DIC or reduced platelets;\n4. those receiving exogenous plasma at the time of the trial;",{"count":114,"type":22},50,"The goal of this observational study is to compare the number of CTCs enriched by both sampling methods, leukapheresis and collection of peripheral blood in metastatic prostate cancer patients. The main questions it aims to answer are:\n\n1. The advantages and disadvantages of two sampling methods for further diagnosis and treatment;\n2. How to obtain further information on the tumour biology of CTC;\n3. The mechanisms of prostate cancer invasion and metastasis Participants will have 7.5mL of peripheral blood taken as well as undergo leukapheresis.",[117,118,119],"Prostate Cancer","Circulating Tumor Cell","Leukapheresis",{"date":100,"type":39},{"date":122,"type":39},"2024-06-25",{"date":124,"type":22},"2028-12-31",{"name":45,"class":46},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":144,"locationsCount":47},"100539651","cytoreductive-prostatectomy-for-poly-metastatic-hormone-sensitive-prostate-cancer-100539651","NCT06306612","CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer","Systemic Therapy Combined With Cytoreductive Prostatectomy for the Treatment of de Novo Poly-metastatic Hormone Sensitive Prostate Cancer: A Prospective, Open-label Randomized Controlled Trial","CREATIVE","Inclusion Criteria:\n\n1. Fully understand the purpose of this trial and sign a written informed consent;\n2. Men aged 18-85 years;\n3. have histologically or cytologically confirmed adenocarcinoma of the prostate;\n4. Have multiple metastatic disease, defined as follows: according to RECIST v1.1, metastatic disease was defined as metastatic foci detected on bone scans or measurable lymph nodes or soft tissue or visceral lesions above the aortic bifurcation. Lymph nodes were defined as measurable if their short-axis diameter was ≥15 mm; soft tissue\u002Fvisceral lesions were defined as measurable if their long-axis diameter was ≥10 mm. and total number of metastatic lesions ≥ 5. Patients with only regional lymph node metastases (N1, below the aortic bifurcation) were not eligible for the study.\n5. At the investigator's discretion, patients must meet the indications for ADT and docetaxel;\n6. Patients have not received any prior local or systemic therapy for prostate cancer primary or metastasis.\n7. Eastern Cooperative Oncology Group (ECOG) score of 0-1;\n8. Blood count at screening: hemoglobin ≥ 9.0 g\u002FdL, absolute neutrophil count ≥ 1.5 x 10\\^9\u002FL, and platelet count ≥ 100 x 10\\^9\u002FL (patient has not received any colony-stimulating factor within 4 weeks or a transfusion or blood product within 7 days prior to blood collection)\n9. Serum alanine aminotransferase and\u002For aspartate aminotransferase ≤ 1.5 x Upper limit of normal (ULN), total bilirubin ≤ ULN, creatinine ≤ 2.0 x ULN.\n\nExclusion Criteria:\n\n1. Prior therapy: ADT, second-generation androgen receptor inhibitors, CYP17 enzyme inhibitors, any chemotherapy or immunotherapy for prostate cancer, radiotherapy (external radiation radiotherapy, brachytherapy, or radiopharmaceuticals);\n2. Known hypersensitivity to any of the investigational drugs, or excipients in the preparations;\n3. Contraindication to CT\u002FMRI examination;\n4. Any of the following conditions within 6 months prior to randomization: stroke, myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass grafting, or congestive heart failure (New York Heart Association cardiac function class III or IV);\n5. uncontrolled hypertension as evidenced by a resting systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg after treatment\n6. History of prior malignancy, except basal cell or cutaneous squamous cell carcinoma in complete remission;\n7. History of gastrointestinal disorders or surgery expected to significantly interfere with the absorption of study drug(s);\n8. Active acute and chronic viral hepatitis, known HIV infection;\n9. Prior (28 days prior to initiation of study drug or 5 half-lives of investigational therapy from a prior study, whichever is longer) or concurrent participation in another clinical study of study drug;\n10. Any other serious or unstable medical condition or condition that may interfere with their participation in the study or the evaluation of study results or may jeopardize the safety of the trial and other conditions;\n11. Inability to swallow oral medications;\n12. A close interest in the research center.","85 Years",{"count":136,"type":22},192,[25],"The goal of this clinical trial is to compare systemic therapy combined with cytoreductive prostatectomy with standard of care (SOC) in de novo poly-metastatic hormone sensitive prostate cancer (de novo pmHSPC). The main questions it aims to answer are:\n\n1. To explore the clinical benefit and safety of systemic therapy combined with cytoreductive prostatectomy for patients with de novo pmHSPC.\n2. To explore the characteristics of the subgroup of patients who could benefit more from the above treatment.\n3. To explore the relationship between stage efficacy and clinical prognosis.\n4. To explore the correlation between molecular imaging such as PSMA-PET\u002FCT and its changes with treatment efficacy.\n\nParticipants will undergo systemic therapy combined with cytoreductive prostatectomy.\n\nResearchers will compare systemic therapy combined with cytoreductive prostatectomy with SOC to see the pros and cons of the two strategies.",[117],{"date":100,"type":39},{"date":142,"type":39},"2024-03-21",{"date":124,"type":22},{"name":45,"class":46},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":152,"minAge":18,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":47},"100487014","pre-operative-therapy-in-breast-cancer-100487014","NCT05621564","Pre-operative Therapy in Breast Cancer","The Effect of Pre-operative Therapy on Response and Survival in Breast Cancer","Inclusion Criteria:\n\n* Female, Aged ≥18 years\n* Histologically confirmed primary breast cancer\n* Plan to receive pre-operative therapy\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of neurological or psychological disease, including epilepsy or dementia\n* Not suitable to participate in this study judged by investigators","FEMALE",{"count":154,"type":22},6032,"This is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.",[157],"Breast Cancer","2026-08-02",{"date":160,"type":39},"2026-08-04",{"date":162,"type":39},"2022-11-01",{"date":164,"type":22},"2030-11",{"name":45,"class":46},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100568766","colorectum-digital-system-for-postoperative-quality-improvement-in-colorectal-cancer-100568766","NCT06685497","COLORECTUM+ Digital System for Postoperative Quality Improvement in Colorectal Cancer","Construction and Application of a Digital Postoperative Medical Quality Evaluation and Promotion System for Colorectal Cancer Based on the COLORECTUM+ Model","Inclusion Criteria:\n\n* Over 18 years old.\n* Pathologically confirmed colorectal cancer patients.\n* Underwent surgery at the Colorectal Cancer Diagnosis and Treatment Center, Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Unable to access electronic devices that can connect to the internet or mobile communications.\n* Uncontrolled psychiatric illness.\n* The ECOG score is greater than or equal to 3.\n* Deemed unsuitable for participation by the investigator.",{"count":174,"type":22},236,[25],"This is a single-center, prospective, interventional study. A total of 236 colorectal cancer patients who underwent surgery will be enrolled and followed for 52 weeks. The digital healthcare quality management system, based on the COLORECTUM+ model, will be used for post-treatment quality evaluation and continuous improvement.\n\nPatients will be managed using an Internet+ post-treatment healthcare management platform. The platform integrates AI technology for real-time symptom analysis and alerts. Patients will report symptoms and health data through the platform, which will generate alerts based on symptom severity to guide appropriate interventions. Follow-up assessments will include patient adherence, satisfaction, quality of life, and healthcare utilization.\n\nThe study expects to demonstrate that the digital healthcare quality management system improves follow-up rates, enhances patient adherence, reduces unplanned hospital visits, and increases overall patient satisfaction. The findings aim to provide evidence for the implementation of digital management systems in colorectal cancer post-treatment care, potentially leading to improved long-term outcomes for patients.",[178],"Colorectal Carcinoma",[180,181,182,183],"colorectal carcinoma","follow-up","Ehealth","adherence","2026-07-27",{"date":186,"type":39},"2026-07-28",{"date":188,"type":39},"2024-12-01",{"date":190,"type":22},"2028-06-01",{"name":45,"class":46},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":83,"minAge":18,"maxAge":19,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100649059","phase-2-efficacy-and-safety-of-darolutamide-combined-with-docetaxel-and-adt-as-neoadjuvant-therapy-for-locally-advanced-prostate-cancer-100649059","NCT07730151","Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.","Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer: A Multicenter, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n1. Male, age \\>= 18 years and \\\u003C= 75 years at the time of signing the informed consent form;\n2. Confirmed as prostate cancer by histological or cytological examination, and planned for radical prostatectomy;\n3. Clinical stage conforms to the definition of locally advanced prostate cancer: cT3b-cT4, N0, M0 or any cT, N1, M0 (based on PSMA-PET\u002FCT examination);\n4. Eastern Cooperative Oncology Group (ECOG) performance status score is 0-1;\n5. Expected lifespan \\>= 10 years;\n6. Important laboratory indicators meet the following requirements: a. Hemoglobin \\>= 90 g\u002FL b. Serum total bilirubin \\\u003C= 1.5 times the upper limit of normal value, transaminase (AST\u002FALT) \\\u003C= 2.5 times the upper limit of normal value c. Serum albumin \\>= 30 g\u002FL d. Serum creatinine \\\u003C= 1.5 times the upper limit of normal value e. Absolute neutrophil count \\>= 1.5 x 10\\^9\u002FL, platelet count \\>= 100 x 10\\^9\u002FL;\n7. No difficulty in swallowing (can take the medicine in whole), chronic diarrhea, intestinal obstruction or other factors affecting drug administration and absorption;\n8. No use of opioid analgesics (including codeine, oxycodone, etc.) to relieve cancer pain;\n9. If the spouse is a fertile female, the subject consents to take effective contraceptive measures during the treatment period and for 4 months after the surgery;\n10. The subject voluntarily participates in this trial, signs the informed consent form, and is willing to comply with the requirements of the research protocol throughout the study period.\n\nExclusion Criteria:\n\n1. Pathological diagnosis of neuroendocrine prostate cancer, including small cell carcinoma;\n2. Prior local or systemic treatment for prostate cancer, including but not limited to radiotherapy, chemotherapy, or endocrine therapy;\n3. Confirmed bone metastasis, hepatic metastasis, brain metastasis, or other visceral metastases on imaging;\n4. Known hypersensitivity to the study drugs (active ingredients or excipients) or drugs of the same class;\n5. Contraindications to prednisone acetate or docetaxel, such as active infection, allergy, or other conditions;\n6. Chronic disease requiring prednisone acetate at doses exceeding those specified in the protocol (5 mg orally twice daily, starting 14 days before docetaxel chemotherapy and stopping 3 weeks after the last chemotherapy cycle);\n7. Poorly controlled hypertension despite medication (systolic blood pressure \\>=160 mmHg or diastolic blood pressure \\>=95 mmHg);\n8. Active or symptomatic viral hepatitis or other chronic liver disease; known human immunodeficiency virus (HIV) infection;\n9. History of pituitary or adrenal dysfunction;\n10. Active autoimmune disease requiring hormonal therapy;\n11. Major cardiovascular or cerebrovascular disease within 6 months prior to the start of study treatment, including: severe\u002Funstable angina, myocardial infarction, congestive heart failure \\[New York Heart Association (NYHA) class III or above\\], cerebrovascular accident, or arrhythmia requiring pharmacological treatment;\n12. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n13. Grade ≥2 peripheral sensory or motor neuropathy;\n14. Other malignancies occurring within the past 2 years or currently concurrent malignancies;\n15. Major surgery requiring general anesthesia within 28 days before the first dose;\n16. Treatment with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ketoconazole) or strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital, St. John's wort) that cannot be discontinued, and have not been stopped for at least 7 days before randomization;\n17. History of epilepsy;\n18. Alcohol or drug abuse or dependence;\n19. Participation in another therapeutic clinical study within 1 month before the start of study treatment;\n20. Any other condition that the investigator considers unsuitable for participation in this study;",{"count":200,"type":22},200,[202],"PHASE2","The goal of this study is to evaluate the efficacy and safety of darolutamide combined with docetaxel and ADT compared to docetaxel combined with ADT in treating locally advanced prostate cancer patients scheduled for radical prostatectomy. The participant population includes adult males with locally advanced prostate cancer (cT3b-cT4, N0, M0 or any cT, N1, M0). The main questions it aims to answer are:\n\nDoes the combination of darolutamide, docetaxel, and ADT improve treatment outcomes compared to docetaxel combined with ADT? What are the safety profiles and adverse effects associated with each treatment group? Researchers will compare the control group (docetaxel combined with ADT) to the experimental group (darolutamide combined with docetaxel and ADT) to see if the experimental treatment is more effective.\n\nParticipants will:\n\nReceive either docetaxel combined with ADT or darolutamide combined with docetaxel and ADT for 4 cycles (16 weeks) as neoadjuvant treatment.\n\nUndergo radical prostatectomy after completing the neoadjuvant treatment. Be followed up for 36 months post-surgery to assess treatment efficacy and safety.",[117,205,206],"Prostate","Prostate Cancer Patients","2026-07-22",{"date":186,"type":39},{"date":210,"type":22},"2026-08-01",{"date":212,"type":22},"2031-12-31",{"name":45,"class":46},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":47},"100641028","profunda-femoris-vein-thrombosis-evaluation-and-clearance-to-improve-outcomes-of-endovascular-treatment-for-acute-iliofemoral-deep-vein-thrombosis-100641028","NCT07622199","PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis","PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis: a Multicenter Randomized Controlled Study (The PROTECT Study)","Inclusion Criteria:\n\n1. Age ≥ 18 years and ≤ 85 years;\n2. Diagnosed with acute iliofemoral DVT involving iliac vein, common femoral vein, and PFV (confirmed by preoperative ultrasound, CT venography, or pre-procedural venography);\n3. Time from symptom onset to endovascular treatment ≤ 14 days;\n4. Patient receives endovascular treatment with PMT;\n5. Patient provides written informed consent.\n\nExclusion Criteria:\n\n1. Presence of pre-existing PTS in the limb scheduled for treatment, or a history of symptomatic DVT in the same limb;\n2. Concurrent symptomatic acute DVT involving the iliac vein and\u002For common femoral vein in the contralateral limb;\n3. Known allergy to heparin, low-molecular-weight heparin, contrast media, or other relevant agents;\n4. Concomitant severe pulmonary embolism with hemodynamic compromise, such as hypoxia or hypotension;\n5. Intolerance to endovascular intervention due to concurrent acute systemic illness, severe dyspnea, or other contraindications;\n6. Concomitant severe renal insufficiency with creatinine clearance \\\u003C 30 ml\u002Fmin;\n7. Presence of active bleeding, severe hepatic insufficiency, bleeding diathesis, or other coagulation disorders;\n8. Concomitant severe anemia (hemoglobin \\\u003C 8.0 mg\u002FdL) or thrombocytopenia (platelet count \\\u003C 80,000\u002FmL);\n9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;\n10. Pregnancy;\n11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency) with an estimated life expectancy \\\u003C 24 months;\n12. Participation in another clinical trial of a drug or medical device within the past 1 month that may interfere with the present study;\n13. Unwillingness to participate in this trial.",{"count":222,"type":22},140,[25],"Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS). The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein. Profunda femoris vein thrombosis clearance (PFV-TC) may improve the patency of iliofemoral vein and reduce the occurrence of PTS.",[226],"Deep Vein Thrombosis",[228,229,230,231],"Deep venous thrombosis","Percutaneous mechanical thrombectomy","Post-thrombotic syndrome","Profunda femoris vein","2026-07-19",{"date":234,"type":39},"2026-07-21",{"date":236,"type":39},"2026-06-24",{"date":238,"type":22},"2029-12-31",{"name":45,"class":46},{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":47},"100646183","phase-4-ciprofol-vs-propofol-for-hemodynamic-stability-in-patients-having-general-anesthesia-for-endovascular-thrombectomy-after-ischemic-stroke-100646183","NCT07696208","Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke","Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke: A Multicenter Randomized Open-label Parallel-group Trial (CONSTANCY)","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Clinical diagnosis of AIS.\n3. CT\u002FMRI-confirmed absence of intracranial hemorrhage.\n4. Eligible for EVT.\n5. NIHSS score ≥2.\n6. ASA physical status I-III.\n7. Signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-existing severe neurological deficits (mRS 3-5).\n2. Shock.\n3. Severe cardiac disease.\n4. Contraindications to EVT per AHA guidelines.\n5. Participation in conflicting clinical trials.",{"count":248,"type":22},124,[250],"PHASE4","Endovascular therapy (EVT) improves the prognosis of patients with acute ischemic stroke (AIS). EVT has been established as a standard of care for AIS caused with large vessel occlusion based on numerous randomized controlled trials. However, despite extensive attention to post-EVT blood pressure management as a potentially modifiable factor, the ability to achieve high reperfusion rates does not consistently translate into functional independence for a substantial number of patients. Thus, the focus has turned to the intra-procedural period, where blood pressure management may play a critical but underexamined role in determining functional outcomes independent of post-EVT care.\n\nGuideline recommendation to maintain the blood pressure lowered to 185\u002F110 mmHg before the EVT procedure in patients who have not received intravenous thrombolysis therapy. However, studies of blood pressure before reperfusion in this patient group have produced conflicting results. Thus, although randomized trials evaluating pre-thrombectomy blood pressure targets are yet unavailable, accumulating evidence suggests that active blood pressure lowering before reperfusion may be harmful, which underscores the importance of maintaining hemodynamic stability during the EVT procedure.\n\nIn this context, anesthetic management is a key determinant of intraprocedural blood pressure control. Propofol is the most commonly used general anesthetic during EVT surgery. However, propofol is a powerful venodilator and often provokes hypotension which may be especially detrimental in AIS patients. Ciprofol, a novel anesthetic\u002Fsedative, has been proven to possess excellent efficacy and safety which provides definitive general anesthesia\u002Fsedation while minimizing respiratory and hemodynamic depression. Before and during EVT, patients with hemodynamic stability may have better outcomes. Using ciprofol as the anesthesia agent may reduce the incidence and severity of hemodynamic instability during EVT. Therefore, it is of significant research value to investigate whether the use of ciprofol for general anesthesia is beneficial in AIS patients undergoing EVT.",[253,254],"Hemodynamic Stability","Ischemic Strokes",[256,257,253,258,259,260],"Ciprofol","Propofol","General Anesthesia","Endovascular Thrombectomy","Ischemic Stroke","2026-07-06",{"date":263,"type":39},"2026-07-10",{"date":265,"type":22},"2026-07-01",{"date":267,"type":22},"2028-05-31",{"name":45,"class":46},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":285,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":47},"100645171","phase-2-the-safety-and-efficacy-of-upadacitinib-in-refractory-autoimmune-related-cholangitis-and-atopic-dermatitis-with-moderate-to-severe-itching-100645171","NCT07678645","The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching","Evaluation of the Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis With Moderate to Severe Itching and Refractory Autoimmune Related Cholangitis: a Single Arm, Exploratory Clinical Study","Inclusion Criteria\n\nPatients must meet all of the following criteria to be eligible for enrollment:\n\n1. Aged ≥18 and ≤70 years, of either sex.\n2. Criteria for Atopic Dermatitis (AD)\n\n   Diagnosis of AD according to the Chinese diagnostic criteria for adult AD, defined as meeting the primary criterion (a) plus either criterion (b) or (c) below:\n   1. Presence of symmetrical eczema with a disease duration of more than 6 months.\n   2. Personal and\u002For first-degree family history of atopic diseases (e.g., eczema, allergic rhinitis, asthma, allergic conjunctivitis, etc.).\n   3. At least one of the following laboratory findings: elevated serum total immunoglobulin E (IgE), elevated peripheral blood eosinophil count, or positive allergen-specific IgE.\n\n   Presence of moderate-to-severe pruritus, defined as a Visual Analogue Scale (VAS) score ≥4.\n3. Criteria for Primary Biliary Cholangitis (PBC)\n\n   Diagnosis of PBC according to practice guideline criteria, defined as meeting at least two of the following three criteria:\n   1. Biochemical evidence of cholestasis, primarily elevated alkaline phosphatase (ALP) and\u002For gamma-glutamyl transferase (GGT).\n   2. Positivity for anti-mitochondrial antibody (AMA) or AMA-M2, or positivity for other disease-specific autoantibodies (anti-gp210 or anti-sp100 antibodies).\n   3. Histological evidence of non-suppurative destructive cholangitis and small bile duct destruction.\n\n   Patients must have received a standard regimen of ursodeoxycholic acid (UDCA) for ≥12 months (at a dose of no less than 13-15 mg\u002Fkg\u002Fday) in combination with at least two subsequent-line therapies (including Farnesoid X receptor agonists, peroxisome proliferator-activated receptor agonists, budesonide, or other immunosuppressants) for ≥3 months.\n\n   At screening, ALP ≥1.5 × upper limit of normal (ULN) or GGT ≥5 × ULN.\n4. Criteria for Primary Sclerosing Cholangitis (PSC)\n\nFor large-duct PSC, diagnosis must meet the following criteria:\n\n1. Biliary imaging showing characteristic multifocal, short-segmental, or annular strictures involving both intra- and extrahepatic bile ducts.\n2. At least one of the following clinical manifestations: biochemical evidence of cholestasis (primarily elevated ALP and\u002For GGT); clinical or histological evidence of coexisting inflammatory bowel disease (IBD); or liver histology showing periductal inflammation with fibrosis (i.e., periductal \"onion-skin\" appearance).\n3. Exclusion of secondary sclerosing cholangitis due to other etiologies.\n\nFor small-duct PSC, diagnosis must meet the following criteria:\n\n1. Biochemical evidence of cholestasis with no significant abnormalities on recent biliary imaging.\n2. Liver histology showing typical PSC changes as described above (periductal inflammation with fibrosis \u002F \"onion-skin\" appearance).\n3. Exclusion of other causes of cholestasis. Patients must have received a standard regimen of UDCA for ≥3 months (at a dose of no less than 13-15 mg\u002Fkg\u002Fday). At screening, ALP ≥1.5 × ULN or GGT ≥5 × ULN.\n\nExclusion Criteria\n\nPatients who meet any of the following criteria will be excluded from enrollment:\n\n1. Known concurrent or history of other hepatobiliary diseases, including but not limited to: active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; complete biliary obstruction; acute cholecystitis or symptomatic cholelithiasis; suspected or confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma.\n2. Child-Pugh Class C cirrhosis; evidence of end-stage liver disease, including: history of liver transplantation or being on the liver transplant waiting list; Model for End-Stage Liver Disease (MELD) score \\>20; severe portal hypertension complications (including severe gastric or esophageal varices, refractory or diuretic-resistant ascites, history of variceal bleeding); or other serious cirrhosis-related complications (spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome).\n3. Total bilirubin \\>10 × upper limit of normal (ULN).\n4. Serum creatinine ≥1.5 × ULN and creatinine clearance \\\u003C60 mL\u002Fmin.\n5. Platelet count \\\u003C50 × 10⁹\u002FL.\n6. International normalized ratio (INR) \\>1.5.\n7. Serum albumin \\\u003C3.0 g\u002FdL.\n8. Use of moderate or strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 14 days prior to the first dose of study drug or planned use throughout the study period.\n9. Presence of diseases that may cause non-hepatic elevation of ALP (e.g., Paget's disease of bone) or any condition with an anticipated life expectancy of less than 2 years.\n10. Known drug abuse or alcohol abuse within 6 months prior to the first dose of study drug, defined as weekly alcohol consumption exceeding 14 standard drinks (1 standard drink equivalent to 360 mL beer, 45 mL of 40% distilled spirits, or 150 mL wine).\n11. Unstable concomitant diseases or use of concomitant medications that cannot be maintained on a stable regimen throughout the clinical study period.\n12. Pregnant women, women planning to become pregnant, breastfeeding women, or fertile patients (male or female) who are unwilling to use at least one effective method of contraception from the time of signing informed consent until 30 days after the last dose of study drug.\n13. Participation in any other interventional clinical trial and receipt of any investigational product within 3 months prior to the first dose of study drug.\n14. Positive results for human immunodeficiency virus antibodies (HIV Ab) or Treponema pallidum antibodies (TP Ab).\n15. Any other condition that, in the investigator's judgment, would preclude the patient's participation in this study.","70 Years",{"count":278,"type":22},44,[202],"Cholestatic liver diseases are characterized by jaundice, pruritus, and elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) represent the major autoimmune-driven entities within this category. Without effective intervention, these conditions may progress to liver failure and even death. Ursodeoxycholic acid (UDCA), the first-line therapy for PBC, has been shown to improve prognosis; however, 20%-40% of patients exhibit an inadequate biochemical response. For PSC, no clearly effective pharmacologic agent is currently available. In refractory patients, pruritus often progressively worsens, severely impairing quality of life and treatment adherence, underscoring an urgent need for novel therapeutic approaches that simultaneously address disease control and itch relief.\n\nAutoimmune-associated cholangitis frequently coexists with atopic dermatitis, and in a subset of patients, pruritus may be compounded by dermatologic factors. The pruritus of atopic dermatitis involves the JAK-STAT signaling pathway, which not only serves as a convergent node for pruritic signals but also constitutes a key downstream hub in the immune dysregulation characteristic of cholangitis. Inhibition of this pathway is therefore hypothesized to alleviate pruritus and modulate aberrant immune responses. Case reports have suggested that upadacitinib, a selective JAK inhibitor, may improve biochemical parameters in refractory PBC and exhibit potential anti-fibrotic effects.\n\nTo this end, investigators plan to conduct an exploratory clinical study to systematically evaluate the safety and efficacy of upadacitinib in patients with atopic dermatitis complicated by moderate-to-severe pruritus and refractory autoimmune-associated cholangitis.",[282,283,284],"Primary Biliary Cholangitis (PBC)","Primary Sclerosing Cholangitis (PSC)","Atopic Dermatitis (AD)",[282,283,284,286,287,288,289,290,291,292,293,294],"pruritus","upadacitinib","cholangitis","bile duct diseases","biliary tract diseases","Digestive System Diseases","Cirrhosis, Biliary","Cholangitis, Biliary","Cholangitis, Sclerosing","2026-06-30",{"date":265,"type":39},{"date":298,"type":22},"2026-06-01",{"date":267,"type":22},{"name":45,"class":46},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":276,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":47},"100505232","early-phase-1-dual-target-car-t-cell-treatment-for-refractory-systemic-lupus-erythematosus-sle-patients-100505232","NCT05858684","Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients","Inclusion Criteria:\n\n1. 18-70 years old;\n2. Total score ≥ 10 on the EULAR\u002FACR 2019 SLE classification criteria;\n3. LLDAS response criteria are not achieved after administration with at least two immunosuppressants (including, but not limited to, azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, ciclosporin and iguratimod) and\u002For at least one approved biological agent for more than 6 months.\n4. SELENA-SLEDAI≥8;\n5. Patients with CD19+ B-cell;\n6. Hemoglobin≥85 g\u002FL;\n7. WBC≥2.5×10\\^9\u002FL\n8. NEUT≥1×10\\^9\u002FL;\n9. BPC≥50×10\\^9\u002FL;\n10. AST\u002FALT below 2 times the upper limit of normal; Creatinine clearance ≥30 mL\u002Fmin; blood bilirubin ≤2.0 mg\u002Fdl; echocardiography indicates that the ejection fraction is ≥50%;\n11. Adequate venous access for apheresis, and no other contraindications for leukapheresis;\n12. Women of childbearing age should have a negative serum or urine pregnancy test at screening and baseline. Subjects agree to take effective contraceptive measures during the trial until at least 1 year after CAR-T cells infusion.\n13. Agree to attend follow-up visits as required;\n14. Voluntary participation and informed consent signed by the patient or his\u002Fher legal\u002Fauthorized representative;\n\nExclusion Criteria:\n\n1. Renal disease: severe lupus nephritis (serum creatinine \\> 2.5 mg\u002FdL or 221 μmol\u002FL) within 8 weeks prior to leukapheresis, or subjects who need hemodialysis;\n2. CNS disease: including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident \\[CVA\\], encephalitis or CNS vasculitis, psychiatric patients with depression or suicidal thoughts;\n3. Patients with serious lesions and history of present illness of vital organs such as heart, liver, kidney and blood and endocrine system;\n4. Patients with immunodeficiency, uncontrolled active infections and active or recurrent peptic ulcers;\n5. Received immunosuppressive therapy within 1 week prior to leukapheresis;\n6. Patients with HIV infection; Active infection of hepatitis B virus or hepatitis C virus; Patients with syphilis infection;\n7. The presence or suspicion of an active fungal, bacterial, viral or other infection that cannot be controlled during screening;\n8. Received live vaccine treatment within 4 weeks prior to screening;\n9. Severe allergies or hypersensitivity;\n10. Contraindication to cyclophosphamide in combination with fludarabine;\n11. Subjects who have undergone major surgery within 2 weeks prior to signing the informed consent form, or who are scheduled to have surgery (other than local anesthetic surgery) during the trial or within 2 weeks of the infusion;\n12. cannula or drainage tubes other than central venous catheters;\n13. Pregnant or lactating women, or subjects who plan to have children within 1 year of treatment;\n14. Subjects with prior CD19 or BCMA-targeted therapy\n15. Participated in any clinical study within 3 months prior to enrollment\n16. Subjects with malignant tumour, except for Non-melanoma Skin Cancer with PFS\\>5yr; Cervical Cancer in situ; Bladder Cancer; Breast Cancer;\n17. Any situations that the investigator believes the patients are not suitable for the study.",{"count":308,"type":22},18,[310],"EARLY_PHASE1","This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.",[313],"CAR-T Cell Therapy","2026-05-29",{"date":298,"type":39},{"date":317,"type":39},"2023-05-11",{"date":319,"type":22},"2029-06-10",{"name":45,"class":46},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":331,"conditions":332,"keywords":346,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":354,"locationsCount":47},"100581542","phase-2-trop2-targeted-immunopet-imaging-of-solid-tumors-100581542","NCT06851663","Trop2-targeted immunoPET Imaging of Solid Tumors","Inclusion Criteria:\n\n* Aged 18-75 year-old and of either sex\n* Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.",{"count":328,"type":22},400,[202,330],"PHASE3","This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.",[333,334,335,336,117,337,338,339,340,341,342,343,344,345],"Solid Tumor","Solid Carcinoma","Uroepithelial Carcinoma","Bladder Cancer","Lung Cancer","Nasopharyngeal Cancer","Liver Cancer","Cholangiocarcinoma","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","Thyroid Cancer","Head and Neck Cancer",[347,348,333],"Trophoblast cell surface antigen 2 (Trop2)","ImmunoPET","2026-05-27",{"date":314,"type":39},{"date":352,"type":39},"2024-12-23",{"date":74,"type":22},{"name":45,"class":46},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":362,"targetDuration":364,"studyType":87,"phases":4,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":47},"100637538","comparison-of-different-mechanical-thrombectomy-devices-in-endovascular-treatment-of-acute-iliofemoral-venous-thrombosis-100637538","NCT07622212","Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis","Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)","Inclusion Criteria:\n\n1. Aged between 18 and 85 years;\n2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;\n3. Time from symptom onset to endovascular treatment ≤ 14 days;\n4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;\n5. Patients sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;\n2. Concurrent symptomatic acute DVT involving the iliac vein and\u002For common femoral vein in the contralateral limb;\n3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc.\n4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.\n5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.\n6. Concomitant severe renal insufficiency with creatinine clearance \\\u003C 30 ml\u002Fmin;\n7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.\n8. Concomitant severe anemia (hemoglobin \\\u003C 8.0 mg\u002FdL) or platelet count \\\u003C 80,000\u002FmL;\n9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;\n10. Pregnant women;\n11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy \\\u003C 24 months\n12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;\n13. Patients unwilling to participate in this trial.",{"count":363,"type":22},180,"24 Months","A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.",[226],[228,229,230],"2026-05-26",{"date":370,"type":39},"2026-06-03",{"date":372,"type":39},"2024-01-01",{"date":124,"type":22},{"name":45,"class":46},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":389,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":47},"100637899","phase-2-hero-utuc-intravesical-rc48-after-rnu-for-her2-utuc-100637899","NCT07591805","HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC","A Prospective Phase II Study of Single Postoperative Intravesical Disitamab Vedotin to Prevent Bladder Recurrence After Radical Nephroureterectomy in HER2-Positive Upper Tract Urothelial Carcinoma","HERO-UTUC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically or radiologically suspected UTUC planned for RNU\n3. HER2-positive tumor defined as IHC 1+, 2+, or 3+ on preoperative or surgical specimen testing.\n4. ECOG performance status 0-1.\n5. No prior or concomitant bladder urothelial carcinoma within 5 years.\n6. Adequate hematologic, hepatic, and renal function.\n7. Ability to comply with protocol-required surveillance.\n8. Written informed consent. -\n\nExclusion Criteria:\n\n1.Evidence of metastatic disease before enrollment. 2.Prior treatment with disitamab vedotin. 3.Prior intravesical anti-cancer therapy within 12 months. 4.Active uncontrolled infection. 5.Pregnancy or breastfeeding. 6.Severe uncontrolled cardiovascular, pulmonary, hepatic, or systemic disease. 7.Known hypersensitivity to study drug components. 8.Any condition that, in the investigator's judgment, would compromise participation or interpretation.\n\n\\-",{"count":384,"type":22},49,[202],"This is a prospective, single-center, single-arm phase II study evaluating whether a single postoperative intravesical instillation of disitamab vedotin (RC48) can reduce bladder recurrence after radical nephroureterectomy (RNU) in patients with HER2-positive upper tract urothelial carcinoma (UTUC). Eligible patients will receive one intravesical instillation of RC48 within 96 hours after surgery. The primary objective is to determine the 12-month intravesical recurrence rate. Serial urine samples will be prospectively collected to evaluate urinary methylation biomarkers for early recurrence detection.",[388],"Upper Urinary Tract Urothelial Carcinoma",[388,390,391,392],"Bladder Recurrence","Disitamab Vedotin","Radical Nephroureterectomy","2026-05-15",{"date":395,"type":39},"2026-05-18",{"date":397,"type":22},"2026-05-16",{"date":399,"type":22},"2028-01-31",{"name":45,"class":46},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":410,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":423,"locationsCount":4},"100637100","phase-2-neoadjuvant-pd-l1-inhibitor-plus-anlotinib-for-kidney-preservation-in-complex-renal-cell-carcinoma-100637100","NCT07602101","Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma","Neoadjuvant PD-L1 Blockade Combined With Anlotinib to Enable Nephron-Sparing Surgery in Patients With High-Complexity Locally Advanced Clear Cell Renal Cell Carcinoma","Inclusion Criteria:\n\n* • Age ≥18 years\n\n  * ECOG performance status 0-2\n  * Histologically confirmed clear cell renal cell carcinoma\n  * Clinical stage cT2-T3aN0M0 (AJCC 8th edition)\n  * RENAL nephrometry score ≥10\n  * Tumor assessed as requiring radical nephrectomy or complex partial nephrectomy\n  * Adequate organ function\n  * Signed informed consent\n\nExclusion Criteria:\n\n* • Prior systemic therapy for RCC (including ICIs or TKIs)\n\n  * Non-clear cell histology or sarcomatoid\u002Frhabdoid differentiation \\>20%\n  * Active autoimmune disease requiring systemic therapy\n  * Active uncontrolled infection (HBV\u002FHCV\u002FHIV)\n  * Prior organ transplantation\n  * Uncontrolled cardiovascular or pulmonary disease\n  * Pregnancy or breastfeeding",{"count":409,"type":22},33,[202],"This is a prospective, multicenter, single-arm phase II study evaluating the efficacy and safety of neoadjuvant PD-L1 inhibitor TQB2450 in combination with anlotinib in patients with locally advanced, high-complexity (RENAL score ≥10) clear cell renal cell carcinoma (ccRCC).\n\nThe primary objective is to determine whether neoadjuvant therapy can increase the rate of successful nephron-sparing surgery.\n\nIn addition, this study incorporates a pre-specified translational research platform including circulating tumor DNA (ctDNA) methylation-based minimal residual disease (MRD) monitoring, tumor multi-omics profiling, and radiomics analysis. Artificial intelligence-based models will be developed to predict treatment response and surgical conversion, enabling precision neoadjuvant strategies.",[413],"Clear Cell Renal Cell Carcinoma",[413,415,30,416,417],"Neoadjuvant Therapy","Anlotinib","Nephron-Sparing Surgery",{"date":419,"type":39},"2026-05-22",{"date":421,"type":22},"2026-05-31",{"date":124,"type":22},{"name":45,"class":46},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":47},"100623414","phase-2-neoadjuvant-ql1706-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer-100623414","NCT07396324","Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer","NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial","NEO-ITHRAN","Inclusion Criteria:\n\n* Aged ≥18 years\n* Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period",{"count":433,"type":22},55,[202],"This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer.",[437],"HR-positive\u002FHER2-negative Breast Cancer","2026-05-10",{"date":440,"type":39},"2026-05-13",{"date":442,"type":39},"2026-05-01",{"date":444,"type":22},"2031-12",{"name":45,"class":46},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":152,"minAge":18,"maxAge":276,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":463,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":47},"100614753","phase-2-neoadjuvant-serplulimab-plus-weekly-paclitaxel-and-carboplatin-in-tnbc-neo-serpent-100614753","NCT07283692","Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial","Inclusion Criteria:\n\n* Female, Aged ≥18 and ≤70 years\n* Histologically confirmed triple negative breast cancer (ER\\\u003C10%, PR\\\u003C10%, and HER2 negative)\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period",{"count":454,"type":22},46,[202],"This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.",[458],"Triple Negative Breast Cancer",[460,461,462],"breast cancer","neoadjuvant","serplulimab",{"date":440,"type":39},{"date":465,"type":39},"2026-03-01",{"date":467,"type":22},"2031-09",{"name":45,"class":46},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":152,"minAge":18,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":47},"100503178","rc48-adc-in-her2-low-advanced-breast-cancer-100503178","NCT05831878","RC48-ADC in HER2-low Advanced Breast Cancer","Disitamab Vedotin (RC48-ADC) in Patients With HER2-low Advanced Breast Cancer","Inclusion Criteria:\n\n* Female patients aged ≥18 years\n* Expected survival ≥12 weeks\n* ECOG 0-1\n* Histologically confirmed invasive advanced or metastatic breast cancer that is incurable and unresectable\n* At least one measurable lesion according to the RECIST 1.1\n* No history of antibody-drug conjugate use\n* Up to one previous chemotherapy for advanced disease\n* Available hormone receptor status. Hormone receptor-positive subjects are allowed to receive no more than two previous endocrine therapy for advanced disease\n* HER2-low tumors, defined as IHC1+ or IHC2+ with negative FISH test; or HER2-ultralow tumors, defined as incomplete and faint membrane staining in \\>0 but ≤10% of tumor cells\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of thromboembolic events\n* Uncontrolled systemic diseases, including diabetes, hypertension, interstitial lung disease, cirrhosis, etc.\n* Active infections requiring systemic treatment\n* Pregnant or lactating\n* Presence of brain metastases and\u002For carcinomatous meningitis",{"count":477,"type":22},36,[25],"To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.",[481],"Advanced Breast Cancer",{"date":440,"type":39},{"date":484,"type":39},"2023-05-04",{"date":74,"type":22},{"name":45,"class":46},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":506,"leadSponsor":507,"locationsCount":47},"100638386","phase-2-biomarker-enriched-kidney-preserving-strategy-with-disitamab-vedotin-plus-tislelizumab-in-her2-positive-high-risk-upper-tract-urothelial-carcinoma-100638386","NCT07584733","Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma","A Prospective, Multicentre, Single-Arm Phase II Study Evaluating a Response-Adapted Kidney-Preserving Strategy Using Neoadjuvant Disitamab Vedotin Plus Tislelizumab in Patients With HER2-Positive High-Risk Upper Tract Urothelial Carcinoma (DISTINCT-II)","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Histologically confirmed upper tract urothelial carcinoma (UTUC) arising from the renal pelvis or ureter, based on ureteroscopic biopsy.\n* High-risk UTUC, defined by at least one of the following features: Tumour size ≥2 cm; High-grade cytology or biopsy; Radiographic evidence of local invasion (≥cT2); Hydronephrosis; Multifocal disease\n* Clinical stage cT1-T3, N0-N1, M0, based on radiographic assessment.\n* N1 disease is permitted only if lymph nodes are considered resectable.\n* HER2-positive disease, defined as immunohistochemistry (IHC) score of 1+，2+ or 3+ on tumour tissue, assessed according to predefined criteria.\n* At least one measurable lesion according to RECIST version 1.1.\n* ECOG performance status of 0-1\n* Adequate organ function, including: Hematologic function; Hepatic function; Renal function (no strict upper\u002Flower limit required);\n* Patients must be considered potential candidates for a kidney-preserving treatment strategy, including: Absolute or relative indication for renal preservation (e.g., solitary kidney, baseline renal insufficiency), or Strong preference for kidney preservation after multidisciplinary discussion\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Evidence of distant metastatic disease (M1).\n* Unresectable or bulky nodal disease (≥N2) not amenable to curative-intent surgery.\n* Prior systemic therapy for urothelial carcinoma, including:Chemotherapy; Immunotherapy; HER2-targeted therapy.\n* Prior radical nephroureterectomy for current disease.\n* Active autoimmune disease requiring systemic treatment within the past 2 years.\n* Current use of immunosuppressive medication, excluding physiologic doses of corticosteroids.\n* Uncontrolled intercurrent illness, including but not limited to: Active infection requiring systemic therapy; Uncontrolled cardiovascular disease; Significant pulmonary disease\n* Known active hepatitis B, hepatitis C, or HIV infection with uncontrolled viral replication.\n* History of another malignancy within the past 5 years, except: Adequately treated basal cell carcinoma; Squamous cell skin cancer; In situ carcinoma.\n* Pregnant or breastfeeding women.\n* Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results.",{"count":114,"type":22},[202],"This is a prospective, multicentre, single-arm phase II study evaluating a response-adapted kidney-preserving strategy in patients with HER2-positive high-risk upper tract urothelial carcinoma (UTUC). Patients will receive neoadjuvant disitamab vedotin plus tislelizumab, followed by response-adapted local treatment, including kidney-sparing surgery or radical nephroureterectomy based on predefined criteria.\n\nThe primary objective is to assess whether this multimodal strategy can achieve clinically meaningful oncologic control while preserving renal function, as measured by 1-year kidney-intact event-free survival (KI-EFS). Secondary and exploratory objectives include evaluation of clinical response, survival outcomes, safety, renal function preservation, and longitudinal dynamics of circulating and urinary tumor DNA.",[498],"Upper Tract Urothelial Carcinoma",[500,501,391,502],"upper tract urothelial carcinoma","Kidney-Preserving","Tislelizumab","2026-05-07",{"date":440,"type":39},{"date":421,"type":22},{"date":124,"type":22},{"name":45,"class":46},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":528,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":535,"locationsCount":47},"100581617","phase-2-cd70-targeted-immunopet-imaging-of-malignant-cancers-100581617","NCT06852638","CD70-targeted immunoPET Imaging of Malignant Cancers","CD70-targeted PET\u002F CT in the Diagnosis of Malignant Cancers","Inclusion Criteria:\n\n* Aged 18-80 year-old and of either sex；\n* Histologically confirmed diagnosis of renal cancer (especially ccRCC)\u002Flymphoma\u002FNPC or suspected renal cancer\u002Flymphoma\u002FNPC by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","80 Years",{"count":517,"type":22},300,[202],"This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.",[521,522,523,524,525,526,527],"Renal Cancer","Renal Clear Cell Carcinoma","Lymphoma","Lymphoma, Large B-Cell, Diffuse","Follicular Lymphoma","Mantle Cell Lymphoma","Nasopharyngeal Carcinoma",[529,348,521,523,527],"The cluster of differentiation (CD70)",{"date":531,"type":39},"2026-05-12",{"date":352,"type":39},{"date":534,"type":22},"2026-12-23",{"name":45,"class":46},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":554,"locationsCount":47},"100641042","a-survey-on-growth-development-in-children-after-liver-transplantation-100641042","NCT07574398","A Survey on Growth Development in Children After Liver Transplantation","Longitudinal Study on Physical Growth in Children After Liver Transplantation","Inclusion Criteria:\n\n* Children with end-stage liver disease of various etiologies requiring liver transplantation.\n* Approved by the ethics committee, and written informed consent has been obtained from the parents\u002Flegal guardians.\n* Age ≤ 1 year (infancy).\n\nExclusion Criteria:\n\n* Age older than 1 year old.\n* Accept liver kidney combined transplantation surgery or second liver transplantation surgery.","1 Year",{"count":545,"type":22},275,"A single-center, large-sample, long-term longitudinal study was conducted to explore the trends and characteristics of changes in growth, development in pediatric liver transplant recipients, with the aim of guiding the development of intervention strategies and optimizing follow-up protocols.",[548],"Growth, Development in Pediatric Liver Transplant Recipients","2026-05-04",{"date":503,"type":39},{"date":552,"type":39},"2024-11-20",{"date":238,"type":22},{"name":45,"class":46},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":563,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":4},"100634287","eeg-tms-for-postoperative-delirium-after-cardiac-surgery-100634287","NCT07537725","EEG-TMS for Postoperative Delirium After Cardiac Surgery","Transcranial Magnetic Stimulation for Postoperative Delirium After Cardiac Surgery: A Prospective, Single-Center, Randomized Double-Blind Controlled Study","RECOVER-C","Inclusion Criteria:\n\n* Aged 50 years or older;\n* undergoing cardiac surgery with cardiopulmonary bypass (coronary artery bypass grafting, aortic valve replacement, mitral valve surgery, or combined procedures);\n* positive assessment by CAM-ICU postoperatively.\n\nExclusion Criteria:\n\n* Chronic antipsychotic treatment;\n* Receipt of antipsychotic medication before enrollment;\n* Patients with permanent loss of autonomy;\n* Not suitable for delirium assessment: including language disorder, deafness, blindness, aphasia, or coma;\n* Withdrawal of treatment or brain death;\n* Known pregnancy or breastfeeding;\n* Unable to provide consent according to national regulations;\n* Patients involuntarily hospitalized by regulatory authorities (compulsory measures);\n* Alcohol-induced delirium \u002F delirium tremens;\n* Contraindications to transcranial magnetic stimulation, including intracranial or cervical metal implants, history of brain surgery, history of epilepsy, cardiac pacemaker or implantable cardioverter-defibrillator, cochlear implant, known intracranial space-occupying lesions, cardiac pacemaker implantation, recent stroke (\\\u003C3 months);\n* Acute infectious diseases;\n* Preoperative severe hemodynamic instability (e.g., requiring intra-aortic balloon pump or extracorporeal membrane oxygenation support).","50 Years",{"count":58,"type":22},[25],"This is a prospective, single-center, randomized, double-blind, sham-controlled trial evaluating the safety and efficacy of transcranial magnetic stimulation (TMS) for the treatment of postoperative delirium in patients undergoing cardiac surgery with extracorporeal circulation. Eligible patients aged 50 years or older who develop delirium after surgery, as assessed by the CAM-ICU, will be randomized to receive either active TMS or sham stimulation. The intervention consists of three daily cycles of intermittent and continuous theta burst stimulation over five days. The primary outcome is the duration of delirium within the five-day intervention period. Secondary outcomes include delirium severity, time to successful discharge, and survival at 30 and 90 days. A total of 144 participants will be enrolled.",[568],"Delirium",{"date":570,"type":39},"2026-04-17",{"date":572,"type":22},"2026-04-27",{"date":574,"type":22},"2027-03-31",{"name":45,"class":46},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":585,"conditions":586,"keywords":589,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":47},"100627612","retrospective-analysis-of-acute-pancreatitis-after-percutaneous-mechanical-thrombectomy-in-treatment-of-thrombotic-disorders-100627612","NCT07450898","Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders","Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders (The RATIO Study)","Inclusion Criteria:\n\n* Patients over 18 years old;\n* Patients with thrombotic peripheral vascular diseases treated by percutaneous mechanical thrombectomy;\n* Patients developed acute pancreatitis within 14 days after percutaneous mechanical thrombectomy;\n* Patients with written informed consent.\n\nExclusion Criteria:\n\n* Patients with acute pancreatitis attributed to other confirmed causes;\n* Patients unable or unwilling to participate in the study.",{"count":584,"type":22},10,"Acute pancreatitis is a rare complication after percutaneous mechanical thrombectomy in treatment of thrombotic disorders. The objectives of this study include: (1) Determine the incidence and severity of acute pancreatitis after percutaneous mechanical thrombectomy; (2) Identify patient\u002Fprocedural risk factors; (3) Evaluate clinical outcomes; (4) Develop a diagnosis and treatment pathway.",[587,588],"Acute Pancreatitis (AP)","Thrombotic Disorders",[590],"Thrombectomy","2026-03-03",{"date":593,"type":39},"2026-03-05",{"date":595,"type":39},"2016-01-01",{"date":597,"type":22},"2026-12-31",{"name":45,"class":46},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":606,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":47},"100627527","biochemical-response-and-clinical-outcomes-in-patients-with-pbc-100627527","NCT07449793","Biochemical Response and Clinical Outcomes in Patients With PBC","Impact of Enhanced Biochemical Response on Clinical Outcomes in Patients With Primary Biliary Cholangitis: A Bidirectional Cohort Study","Inclusion Criteria:\n\n* Age above 18 years old, Male or Female,\n* Diagnosis of PBC meeting the 2018 American Association for the Study of Liver Diseases (AASLD) Practice Guidelines criteria;\n* Treatment with UDCA at a standard dose (13-15 mg\u002Fkg\u002Fday), with or without other second-line medications.\n\nExclusion Criteria:\n\n* Co-existing liver diseases, including but not limited to: Hepatitis C virus infection; Active Hepatitis B infection (patients who are HBsAg-negative and HBeAg-negative may be considered eligible per investigator assessment);\n* Autoimmune Hepatitis (AIH); Primary Sclerosing Cholangitis (PSC); Suspected or confirmed hepatocellular carcinoma;\n* Female subjects who is pregnant or breastfeeding during the study;\n* History of other malignancies, including hematological tumors, solid tumors except hepatobiliary system;\n* Poor adherence or inability to complete the study follow-up.",{"count":607,"type":22},3000,"This study is a bidirectional cohort study. The investigators conduct a bidirectional cohort study utilizing a database in mainland China, continuously collecting demographics, clinical symptoms, and biochemical characteristics of diagnosed PBC patients.\n\nThe study aims to analyze the association between varying post-treatment alkaline phosphatase (AKP) levels and complication-free survival rates, with the objective to develop and validate a predictive survival model.",[282,610],"Primary Biliary Cholangitis",[612,613,614,615,291,293,292,616],"Primary Biliary Cirrhosis","Cholangitis","Bile Duct Diseases","Biliary Tract Diseases","Chronic Nonsuppurative Destructive Cholangitis","2026-02-26",{"date":619,"type":39},"2026-03-04",{"date":621,"type":22},"2026-02-01",{"date":399,"type":22},{"name":45,"class":46},""]